Jason S Fisherman Net Worth

The estimated Net Worth of Jason S Fisherman is at least $2.41 Milión dollars as of 14 November 2019. Jason Fisherman owns over 20,000 units of Exelixis Inc stock worth over $2,396,700 and over the last 21 years Jason sold EXEL stock worth over $16,418.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jason Fisherman EXEL stock SEC Form 4 insiders trading

Jason has made over 12 trades of the Exelixis Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Jason exercised 20,000 units of EXEL stock worth $65,600 on 14 November 2019.

The largest trade Jason's ever made was exercising 20,000 units of Exelixis Inc stock on 14 November 2019 worth over $65,600. On average, Jason trades about 2,709 units every 152 days since 2003. As of 14 November 2019 Jason still owns at least 90,000 units of Exelixis Inc stock.

You can see the complete history of Jason Fisherman stock trades at the bottom of the page.

What's Jason Fisherman's mailing address?

Jason's mailing address filed with the SEC is C/O ACHILLION PHARMACEUTICALS, INC., 1777 SENTRY PARKWAY W, BLDG 14, STE 200, BLUE BELL, PA, 19422.

Insiders trading at Exelixis Inc

Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey a Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.

What does Exelixis Inc do?

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.

Complete history of Jason Fisherman stock trades at Exelixis Inc

Exelixis Inc executives and stock owners

Exelixis Inc executives and other stock owners filed with the SEC include:

• Dr. Michael M. Morrissey,
  CEO, Pres & Director
• Michael Morrissey,
  President, Chief Executive Officer, Director
• Gisela Schwab,
  President - Product Development and Medical Affairs, Chief Medical Officer
• Christopher J. Senner,
  Exec. VP & CFO
• Christopher Senner,
  Chief Financial Officer, Executive Vice President
• Jeffrey J. Hessekiel,
  Exec. VP, Gen. Counsel & Sec.
• Jeffrey Hessekiel,
  Executive Vice President, General Counsel
• Patrick J. Haley M.B.A., MBA,
  Exec. VP of Commercial
• Peter Lamb,
  Executive Vice President - Scientific Strategy, Chief Scientific Officer
• Stelios Papadopoulos,
  Independent Chairman of the Board, Co-Founder
• Charles Cohen,
  Independent Director
• Jack Wyszomierski,
  Independent Director
• George Poste,
  Independent Director
• Vincent Marchesi,
  Independent Director
• Julie Smith,
  Independent Director
• Alan Garber,
  Independent Director
• Maria Freire,
  Independent Director
• Carl Feldbaum,
  Independent Director
• Lance Willsey,
  Independent Director
• Dr. Stelios Papadopoulos Ph.D.,
  Co-Founder & Independent Chairman
• Patrick Haley,
  Executive Vice President - Commercial
• Laura Dillard,
  Exec. VP of HR
• Gregg Bernier,
  VP of Marketing
• Susan T. Hubbard,
  Exec. VP of Public Affairs & Investor Relations
• Dr. Peter Lamb,
  Exec. VP of Scientific Strategy & Chief Scientific Officer
• Dr. Dana T. Aftab,
  Exec. VP of Bus. Operations
• George A Scangos,
  Director
• Dana Aftab,
  CSO/EVP Disc & Trans Research
• Mary C Beckerle,
  Director
• David Edward Caligan Partne...,
  
• Sue Gail Eckhardt,
  Director
• Bob Oliver,
  Director
• Tomas J. Heyman,
  Director
• Jacqueline Wright,
  Director
• Pamela A Simonton,
  VP, Corp Tech Development
• Frank Karbe,
  Senior VP & CFO
• Deborah Burke,
  SVP & Chief Financial Officer
• Jeffrey Latts,
  Sr VP, Chief Medical Officer
• Peter Stalder,
  Director
• Jason S Fisherman,
  Director
• Kristine M Ball,
  Controller & Interim CFO
• Frank Mccormick,
  Director
• Steven P James,
  Sr VP, Commercial Ops
• Jane M Green,
  VP, Corp Communications
• Glen Y Sato,
  CFO Sec and General Counsel
• Jean Francois Formela,
  Director
• Lupe M Rivera,
  VP, HUMAN RESOURCES
• Frances K Heller,
  EVP, Business Development
• Ian D Malcolm,
  VP, STRATEGIC MARKETING
• Christoph Pereira,
  VP, Legal Affairs & Secretary
• J. Scott Garland,
  EVP & Chief Commerical Officer
• Gregory Plowman,
  Sr VP, Research
• Geoffrey M Duyk,
  Pres R&D & Chief Sc Off
• Vicki L Goodman,
  EVP, Prod Dev & Med Aff &CMO
• Amy C. Peterson,
  EVP Prod Dev & Med Aff & CMO